Trial ID or NCT#

NCT02628535

Status

RECRUITING

Purpose

The purpose of this study is to evaluate the safety of MGD009 when given to patients with B7-H3-expressing tumors. The study will also evaluate what is the highest dose of MGD009 that can be given safely. Assessments will be done to see how the drug acts in the body (pharmacokinetics (PK), pharmacodynamics (PD) and to evaluate potential anti-tumor activity of MGD009.

Official Title

Phase 1, First-in-Human, Open Label, Dose Escalation Study of MGD009, A Humanized B7-H3 x CD3 Dual-Affinity Re-Targeting (DART) Protein in Patients With Unresectable or Metastatic B7-H3-Expressing Neoplasms

Eligibility Criteria

Ages Eligible for Study: Older than 18 Years
Sexes Eligible for Study: All
Accepts Healthy Volunteers: No

Investigator(s)

Shivaani Kummar
Medical oncologist, Sarcoma specialist
Professor of Medicine (Oncology) and of Radiology (Molecular Imaging Program at Stanford) at the Stanford University Medical Center
Kristen N Ganjoo
Sarcoma specialist
Associate Professor of Medicine (Oncology) at the Stanford University Medical Center

Contact us to find out if this trial is right for you.

CONTACT

Anastasia Harper
(650) 725-0378